Search

Interstrand cross-links (ICLs) are extremely toxic DNA lesions that create an impassable roadblock to DNA replication. When a replication fork collides with an ICL, it triggers a damage response that promotes multiple DNA processing events required to excise the cross-link from chromatin and resolve the stalled replication fork. One of the first steps in this process involves displacement of the CMG replicative helicase (comprised of Cdc45, MCM2-7, and GINS), which obstructs the underlying crosslink. Here we report that the p97/Cdc48/VCP segregase plays a critical role in ICL repair by unloading the CMG complex from chromatin. Eviction of the stalled helicase involves K48-linked polyubiquitylation of MCM7, p97-mediated extraction of CMG, and a largely degradation-independent mechanism of MCM7 deubiquitylation. Our results show that ICL repair and replication termination both utilize a similar mechanism to displace the CMG complex from chromatin. However, unlike termination, repair- mediated helicase unloading involves the tumor suppressor protein BRCA1, which acts upstream of MCM7 ubiquitylation and p97 recruitment. Together, these findings indicate that p97 plays a conserved role in dismantling the CMG helicase complex during different cellular events, but that distinct regulatory signals ultimately control when and where unloading takes place. [ABSTRACT FROM AUTHOR]

Investigates the role of alanine(B15) in the active site of bombyxin, a hormone from the silkworm Bombyx mori. Replacement of alanine with other alkyl amino acids; Demonstration of the importance of alanine for this site; Possible formation of a contiguous hydrophobic area by the bombyxin receptor binding site.

Bombyxin II, a product of the brain of the adult silkmoth, Bombyx mori, binds to ovarian cells of three different species of lepidoptera, i.e. B. mori (silkmoth), Samia cynthia ricini (ailanthus moth), and an ovarian cell line of Spodoptera frugiperda (Sf9) (fall armyworm). Crude Sf9 cell membrane preparations were used to show that the purported bombyxin receptor binds its ligand in a specific, saturable, and reversible manner. The dissociation constant of the bombyxin-receptor complex is 260±90 pM. Quantitative binding studies and Scatchard analysis suggest that every Sf9 cell displays 20000 receptors on the surface. The cross-linked bombyxin-receptor ligand complex has an apparent molecular mass of about 300 kDa as determined by SDS/PAGE. Reduction causes the bombyxin receptor to dissociate into two subunits with molecular masses of 90 kDa and 116 kDa. The size and subunit structure of the putative bombyxin receptor on Sf9 cells show some similarities to the mammalian insulin receptor. [ABSTRACT FROM AUTHOR]

Hydroxychloroquine (HCQ) and chloroquine are repurposed drugs known to disrupt autophagy, a molecular recycling pathway essential for tumor cell survival, chemotherapeutic resistance, and stemness. We pursued a multi-omic strategy in OVCAR3 ovarian cancer and CCL218 colorectal cancer cells. Two genome-scale screens were performed. In the forward genetic screen, cell populations were passaged for 15 drug pulse-chases with HCQ or vehicle control. Evolved cells were collected and processed for bulk RNA-seq, exome-seq, and single-cell RNA-seq (scRNA-seq). In the reverse genetic screen, a pooled CRISPR-Cas9 library was used in cells over three pulse-chases of HCQ or vehicle control treatments. HCQ evolved cells displayed remarkably few mutational differences, but substantial transcriptional differences. Transcriptomes revealed multiple pathways associated with resistance to HCQ, including upregulation of glycolysis, exocytosis, and chromosome condensation/segregation, or downregulation of translation and apoptosis. The Cas9 screen identified only one autophagy gene. Chromosome condensation and segregation were confirmed to be disrupted by HCQ in live cells and organelle-free in vitro extracts. Transcriptional plasticity was the primary mechanism by which cells evolved resistance to HCQ. Neither autophagy nor the lysosome were substantive hits. Our analysis may serve as a model for how to better position repurposed drugs in oncology. [ABSTRACT FROM AUTHOR]